treatment-resistant depression

Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder. Presented at the American College of Neuropsychopharmacology...

(Part four of a four-part series) See previous stories:  Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS' Published Results Psychedelics And Treatment-Resistant...

(Part one of a four-part series) Results from COMPASS Pathways (NASDAQ: CMPS)’ Phase 2b trial assessing the safety of different doses of proprietary synthetic psilocybin paired with psychotherapy for Treatment-Resistant Depression (TRD) were recently published in the New England Journal of...

Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing.  The round was led by the company’s incubator, RA Capital...

Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).  The randomized, double-blind, placebo-controlled, single-...

Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa. The trial will compare the effects of 25 mg and 1 mg of COMP360 (...

A recent study led by Imperial College London’s Centre for Psychedelic Research found that psilocybin could increase neuroplasticity in cases of treatment-resistant depression (TRD), even more than traditional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs). The...

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of interest in life and a decrease in...

Besides being one of the most intimidating human beings ever to step into the boxing ring, former heavyweight champion Mike Tyson is also in the process of becoming a master at the art of dying. He’s had years of training to get there—as well as the help of a creature called the Sonoran...